Peripheral Arterial Interventional Devices

Global Peripheral Arterial Interventional Devices Market to Reach US$12.3 Billion by 2030

The global market for Peripheral Arterial Interventional Devices estimated at US$8.7 Billion in the year 2024, is expected to reach US$12.3 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Drug-Eluting Stents, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Bare Stents segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 9.2% CAGR

The Peripheral Arterial Interventional Devices market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Peripheral Arterial Interventional Devices Market - Key Trends & Drivers Summarized

Why Are Peripheral Arterial Interventions Critical for Managing Vascular Diseases?

Peripheral arterial interventional devices are used to diagnose and treat blockages or narrowing in arteries outside the heart, primarily in the limbs. These devices include angioplasty balloons, stents, atherectomy systems, guidewires, embolic protection devices, and drug-coated technologies. They are essential in treating peripheral artery disease (PAD), which affects circulation, mobility, and limb viability, especially in elderly and diabetic patients.

Minimally invasive peripheral interventions help restore blood flow, prevent limb amputation, and reduce symptoms such as claudication or ischemic ulcers. As PAD remains underdiagnosed yet increasingly prevalent worldwide, especially in aging populations, the need for reliable interventional solutions is growing in both primary and secondary vascular care settings.

How Are Devices Being Optimized for Complex and Recurrent Arterial Lesions?

Technological innovation in interventional tools has focused on navigating calcified, tortuous, or long lesions with minimal trauma. Drug-coated balloons (DCBs) and drug-eluting stents (DES) are becoming standard in femoropopliteal procedures due to their ability to inhibit restenosis. Atherectomy systems are being refined to debulk plaque effectively without damaging the vessel wall, supporting better long-term outcomes in heavily calcified arteries.

Wire-guided catheters, steerable sheaths, and real-time intravascular imaging tools are enhancing procedural accuracy. Bioabsorbable scaffolds and hybrid stents are under investigation for use in younger patients or those with high restenosis risk. Moreover, integrated procedural kits, including crossing devices and closure systems, are reducing procedural time and simplifying interventions in outpatient settings.

Where Is Clinical Use Expanding and Which Conditions Are Fueling Device Adoption?

Interventions for PAD are expanding rapidly across vascular centers, ambulatory surgical centers, and hybrid operating suites. North America and Europe lead in terms of adoption, owing to established PAD screening and reimbursement programs. However, Asia-Pacific is emerging as a high-growth region due to increasing incidence of diabetes, hypertension, and obesity-related vascular conditions.

Critical limb ischemia, chronic total occlusions, and complex femoral and below-the-knee lesions are key drivers of device use. As awareness improves among general practitioners and cardiologists, more patients are being referred earlier for diagnostic angiography and interventional management. Device demand is also increasing in high-risk populations with renal impairment, post-surgical graft occlusions, or failed prior stenting.

Growth in the Peripheral Arterial Interventional Devices market is driven by several factors…

Growth in the peripheral arterial interventional devices market is driven by factors such as rising global prevalence of PAD, increasing preference for minimally invasive procedures, and continued innovation in drug-coated and atherectomy technologies. Improvements in procedural techniques, stent durability, and imaging guidance are making interventions safer and more effective across a wider range of patients.

Expansion of outpatient interventional programs, adoption of same-day discharge protocols, and integration of advanced closure systems are supporting market growth. As patient populations age and chronic vascular diseases become more prevalent, demand for specialized, high-precision peripheral intervention tools continues to increase. Clinical guidelines supporting early PAD intervention and technological progress in next-generation devices are reinforcing long-term growth in this segment.

SCOPE OF STUDY:

The report analyzes the Peripheral Arterial Interventional Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Drug-Eluting Stents, Bare Stents, Ordinary Balloon, Drug-Eluting Balloon, Special Balloon); Application (Lower Limbs Application, Renal Artery Application, Carotid Artery Application)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• AngioDynamics Inc.
• B. Braun Melsungen AG
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• Cardinal Health Inc.
• Cardinal Health (Cordis)
• Cook Medical
• Gore Medical (W. L. Gore & Associates)
• iVascular S.L.U.
• Kaneka Corporation
• Medtronic plc
• Merit Medical Systems Inc.
• MicroPort Scientific Corporation
• Penumbra Inc.
• Philips (Philips Healthcare)
• Shockwave Medical Inc.
• Surmodics Inc.
• Teleflex Incorporated
• Terumo Corporation

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.